PARP-1 regulates DNA repair factor availability

Matthew J. Schiewer, Amy C. Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, Renée de Leeuw, Shuang G. Zhao, Joseph Evans, Sumin Han, Theodore Parsons, Ruth Birbe, Peter McCue, Christopher McNair, Saswati N. Chand, Ylenia Cendon-Florez, Peter Gallagher, Jennifer J. McCann, Neermala Poudel Neupane, Ayesha A. Shafi, Emanuela DylgjeriLucas J. Brand, Tapio Visakorpi, Ganesh Raj, Costas D. Lallas, Edouard J. Trabulsi, Leonard G. Gomella, Adam P. Dicker, Wm Kevin Kelly, Benjamin E. Leiby, Beatrice Knudsen, Felix Y. Feng, Karen E. Knudsen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic activity. Further investigation of the PARP-1-regulated transcriptome and secondary strategies for assessing PARP-1 activity in patient tissues revealed that PARP-1 activity was unexpectedly enriched as a function of disease progression and was associated with poor outcome independent of DNA double-strand breaks, suggesting that enhanced PARP-1 activity may promote aggressive phenotypes. Mechanistic investigation revealed that active PARP-1 served to enhance E2F1 transcription factor activity, and specifically promoted E2F1-mediated induction of DNA repair factors involved in homologous recombination (HR). Conversely, PARP-1 inhibition reduced HR factor availability and thus acted to induce or enhance “BRCA-ness”. These observations bring new understanding of PARP-1 function in cancer and have significant ramifications on predicting PARP-1 inhibitor function in the clinical setting.

Original languageEnglish (US)
Article numbere8816
JournalEMBO Molecular Medicine
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Homologous Recombination
DNA Repair
E2F1 Transcription Factor
Double-Stranded DNA Breaks
Transcriptome
DNA Damage
Chromatin
Disease Progression
Neoplasms
Phenotype
Poly(ADP-ribose) Polymerase Inhibitors

Keywords

  • DNA repair
  • E2F1
  • PARP
  • transcription

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Schiewer, M. J., Mandigo, A. C., Gordon, N., Huang, F., Gaur, S., de Leeuw, R., ... Knudsen, K. E. (2018). PARP-1 regulates DNA repair factor availability. EMBO Molecular Medicine, 10(12), [e8816]. https://doi.org/10.15252/emmm.201708816

PARP-1 regulates DNA repair factor availability. / Schiewer, Matthew J.; Mandigo, Amy C.; Gordon, Nicolas; Huang, Fangjin; Gaur, Sanchaika; de Leeuw, Renée; Zhao, Shuang G.; Evans, Joseph; Han, Sumin; Parsons, Theodore; Birbe, Ruth; McCue, Peter; McNair, Christopher; Chand, Saswati N.; Cendon-Florez, Ylenia; Gallagher, Peter; McCann, Jennifer J.; Poudel Neupane, Neermala; Shafi, Ayesha A.; Dylgjeri, Emanuela; Brand, Lucas J.; Visakorpi, Tapio; Raj, Ganesh; Lallas, Costas D.; Trabulsi, Edouard J.; Gomella, Leonard G.; Dicker, Adam P.; Kelly, Wm Kevin; Leiby, Benjamin E.; Knudsen, Beatrice; Feng, Felix Y.; Knudsen, Karen E.

In: EMBO Molecular Medicine, Vol. 10, No. 12, e8816, 01.12.2018.

Research output: Contribution to journalArticle

Schiewer, MJ, Mandigo, AC, Gordon, N, Huang, F, Gaur, S, de Leeuw, R, Zhao, SG, Evans, J, Han, S, Parsons, T, Birbe, R, McCue, P, McNair, C, Chand, SN, Cendon-Florez, Y, Gallagher, P, McCann, JJ, Poudel Neupane, N, Shafi, AA, Dylgjeri, E, Brand, LJ, Visakorpi, T, Raj, G, Lallas, CD, Trabulsi, EJ, Gomella, LG, Dicker, AP, Kelly, WK, Leiby, BE, Knudsen, B, Feng, FY & Knudsen, KE 2018, 'PARP-1 regulates DNA repair factor availability', EMBO Molecular Medicine, vol. 10, no. 12, e8816. https://doi.org/10.15252/emmm.201708816
Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R et al. PARP-1 regulates DNA repair factor availability. EMBO Molecular Medicine. 2018 Dec 1;10(12). e8816. https://doi.org/10.15252/emmm.201708816
Schiewer, Matthew J. ; Mandigo, Amy C. ; Gordon, Nicolas ; Huang, Fangjin ; Gaur, Sanchaika ; de Leeuw, Renée ; Zhao, Shuang G. ; Evans, Joseph ; Han, Sumin ; Parsons, Theodore ; Birbe, Ruth ; McCue, Peter ; McNair, Christopher ; Chand, Saswati N. ; Cendon-Florez, Ylenia ; Gallagher, Peter ; McCann, Jennifer J. ; Poudel Neupane, Neermala ; Shafi, Ayesha A. ; Dylgjeri, Emanuela ; Brand, Lucas J. ; Visakorpi, Tapio ; Raj, Ganesh ; Lallas, Costas D. ; Trabulsi, Edouard J. ; Gomella, Leonard G. ; Dicker, Adam P. ; Kelly, Wm Kevin ; Leiby, Benjamin E. ; Knudsen, Beatrice ; Feng, Felix Y. ; Knudsen, Karen E. / PARP-1 regulates DNA repair factor availability. In: EMBO Molecular Medicine. 2018 ; Vol. 10, No. 12.
@article{fa4c02deb5a3478997eb5e47958a69d0,
title = "PARP-1 regulates DNA repair factor availability",
abstract = "PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic activity. Further investigation of the PARP-1-regulated transcriptome and secondary strategies for assessing PARP-1 activity in patient tissues revealed that PARP-1 activity was unexpectedly enriched as a function of disease progression and was associated with poor outcome independent of DNA double-strand breaks, suggesting that enhanced PARP-1 activity may promote aggressive phenotypes. Mechanistic investigation revealed that active PARP-1 served to enhance E2F1 transcription factor activity, and specifically promoted E2F1-mediated induction of DNA repair factors involved in homologous recombination (HR). Conversely, PARP-1 inhibition reduced HR factor availability and thus acted to induce or enhance “BRCA-ness”. These observations bring new understanding of PARP-1 function in cancer and have significant ramifications on predicting PARP-1 inhibitor function in the clinical setting.",
keywords = "DNA repair, E2F1, PARP, transcription",
author = "Schiewer, {Matthew J.} and Mandigo, {Amy C.} and Nicolas Gordon and Fangjin Huang and Sanchaika Gaur and {de Leeuw}, Ren{\'e}e and Zhao, {Shuang G.} and Joseph Evans and Sumin Han and Theodore Parsons and Ruth Birbe and Peter McCue and Christopher McNair and Chand, {Saswati N.} and Ylenia Cendon-Florez and Peter Gallagher and McCann, {Jennifer J.} and {Poudel Neupane}, Neermala and Shafi, {Ayesha A.} and Emanuela Dylgjeri and Brand, {Lucas J.} and Tapio Visakorpi and Ganesh Raj and Lallas, {Costas D.} and Trabulsi, {Edouard J.} and Gomella, {Leonard G.} and Dicker, {Adam P.} and Kelly, {Wm Kevin} and Leiby, {Benjamin E.} and Beatrice Knudsen and Feng, {Felix Y.} and Knudsen, {Karen E.}",
year = "2018",
month = "12",
day = "1",
doi = "10.15252/emmm.201708816",
language = "English (US)",
volume = "10",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - PARP-1 regulates DNA repair factor availability

AU - Schiewer, Matthew J.

AU - Mandigo, Amy C.

AU - Gordon, Nicolas

AU - Huang, Fangjin

AU - Gaur, Sanchaika

AU - de Leeuw, Renée

AU - Zhao, Shuang G.

AU - Evans, Joseph

AU - Han, Sumin

AU - Parsons, Theodore

AU - Birbe, Ruth

AU - McCue, Peter

AU - McNair, Christopher

AU - Chand, Saswati N.

AU - Cendon-Florez, Ylenia

AU - Gallagher, Peter

AU - McCann, Jennifer J.

AU - Poudel Neupane, Neermala

AU - Shafi, Ayesha A.

AU - Dylgjeri, Emanuela

AU - Brand, Lucas J.

AU - Visakorpi, Tapio

AU - Raj, Ganesh

AU - Lallas, Costas D.

AU - Trabulsi, Edouard J.

AU - Gomella, Leonard G.

AU - Dicker, Adam P.

AU - Kelly, Wm Kevin

AU - Leiby, Benjamin E.

AU - Knudsen, Beatrice

AU - Feng, Felix Y.

AU - Knudsen, Karen E.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic activity. Further investigation of the PARP-1-regulated transcriptome and secondary strategies for assessing PARP-1 activity in patient tissues revealed that PARP-1 activity was unexpectedly enriched as a function of disease progression and was associated with poor outcome independent of DNA double-strand breaks, suggesting that enhanced PARP-1 activity may promote aggressive phenotypes. Mechanistic investigation revealed that active PARP-1 served to enhance E2F1 transcription factor activity, and specifically promoted E2F1-mediated induction of DNA repair factors involved in homologous recombination (HR). Conversely, PARP-1 inhibition reduced HR factor availability and thus acted to induce or enhance “BRCA-ness”. These observations bring new understanding of PARP-1 function in cancer and have significant ramifications on predicting PARP-1 inhibitor function in the clinical setting.

AB - PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic activity. Further investigation of the PARP-1-regulated transcriptome and secondary strategies for assessing PARP-1 activity in patient tissues revealed that PARP-1 activity was unexpectedly enriched as a function of disease progression and was associated with poor outcome independent of DNA double-strand breaks, suggesting that enhanced PARP-1 activity may promote aggressive phenotypes. Mechanistic investigation revealed that active PARP-1 served to enhance E2F1 transcription factor activity, and specifically promoted E2F1-mediated induction of DNA repair factors involved in homologous recombination (HR). Conversely, PARP-1 inhibition reduced HR factor availability and thus acted to induce or enhance “BRCA-ness”. These observations bring new understanding of PARP-1 function in cancer and have significant ramifications on predicting PARP-1 inhibitor function in the clinical setting.

KW - DNA repair

KW - E2F1

KW - PARP

KW - transcription

UR - http://www.scopus.com/inward/record.url?scp=85058006502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058006502&partnerID=8YFLogxK

U2 - 10.15252/emmm.201708816

DO - 10.15252/emmm.201708816

M3 - Article

C2 - 30467127

AN - SCOPUS:85058006502

VL - 10

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 12

M1 - e8816

ER -